Skip to main content
. 2012 Jan 13;103(3):587–592. doi: 10.1111/j.1349-7006.2011.02175.x

Figure 1.

Figure 1

 Overall survival (OS) and progression‐free survival (PFS) curves for patients with grade 2 and 3 gliomas with or without 1p/19q loss of heterozygosity (LOH) and/or isocitrate dehydrogenase (IDH) mutation. Overall survival (A) and PFS (B) in grade 2 gliomas; OS (C) and PFS (D) in grade 3 gliomas.